US 7668730

I'll search for the specific patent number and any associated litigation.

Let me search specifically for CAFC 2026 appellate dockets and any recent USPTO proceedings involving this patent.

US Patent 7,668,730 — Analyst Summary

Sourcing note: I searched for the exact identifier 7668730 / 7,668,730. I was able to retrieve the Google Patents full text (which I treat as authoritative here), USPTO/PTAB filings, and the Federal Circuit opinion. I could not retrieve a live USPTO Patent Center record or a CAFC 2026 docket entry for this patent — see "CAFC 2026 docket" below, where I flag that explicitly rather than guess.

Bibliographic data

Abstract (as issued): "A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug."

Specification gist: The patent describes a restricted-distribution program for a "sensitive drug" — the working example throughout is sodium oxybate / gamma hydroxy butyrate (GHB), marketed as Xyrem® — in which a single, exclusive central pharmacy maintains an exclusive central database (referred to in places as "CHIPS") covering all prescriptions, prescribers, and patients. Disclosed controls include prescriber credentialing (DEA/state license, actions against the physician), patient and prescriber education and registry, shipment restricted to the patient's home address with adult signature, US-mail shipping (to invoke mail-fraud exposure), post-delivery receipt confirmation, early-refill scrutiny, cycle-count/inventory reconciliation, and query-based reporting to detect diversion.

Independent claims in plain language

The granted patent has 11 claims total, of which 7 are independent: claims 1, 2, 7, 8, 9, 10, and 11. (Claims 3–6 depend from claim 2.)

• Claim 1 — Exclusive-central-pharmacy pipeline, with education gate. A computer-implemented method in which all prescription requests for the drug, for any and all patients, are received only at a single exclusive central pharmacy from any and all prescribing doctors; that information must be entered into an exclusive computer database, such that all prescriptions are processed only by that pharmacy using only that database; the computer checks prescriber credentials; the patient is confirmed to have read the educational material before shipping; the database is checked for potential abuse; the drug is mailed only if no potential abuse is found for that patient and that doctor; receipt by the patient is confirmed; and the computer generates periodic reports to evaluate potential diversion patterns.

• Claim 2 — Same architecture, trimmed. Substantively the same exclusive-pharmacy / exclusive-database method (receive → enter → credential check → database abuse check → mail only if no abuse → confirm receipt → periodic diversion reports), but omits the express "confirming with the patient that educational material has been read" limitation and does not use the "requiring entering" phrasing.

• Claim 7 — "Authorized prescribers" variant with an added abuse screen. Same exclusive-pharmacy/exclusive-database flow framed around "authorized prescribers," adds confirmation that the patient read the educational material, and expressly requires checking the exclusive database for potential abuse associated with both the patient and the prescribing clinician, with the drug provided only if the database is not indicative of potential abuse by either.

• Claim 8 — GHB-specific. Same structure as claim 7 but reciting gamma hydroxybutyrate (GHB) specifically, with the education confirmation tied to the first time GHB is provided to the patient.

• Claim 9 — GHB-specific, mailing variant. Identical to claim 8 except the delivery step is expressly "mailing GHB to the patient."

• Claim 10 — GHB-specific plus manufacturing/sole-source supply. Adds two upstream steps to the claim 9 framework: manufacturing GHB, and providing the manufactured GHB only to the exclusive central pharmacy — i.e., a closed supply chain feeding the single dispensing point.

• Claim 11 — Generic drug variant, no reporting step. Same exclusive-pharmacy/exclusive-database flow (receive → enter → credential check → education confirmation → database abuse check on patient and prescriber → provide drug only if no potential abuse → confirm receipt), but without the "generating periodic reports" limitation.

Caution on claim sets: The pre-grant publication US 2004/0117205 A1 carries a different claim set — e.g., 25 claims including a "method of obtaining FDA approval for a sensitive drug" and claims to query types (by physician specialty, patient name, frequency, dose). Those are the published application claims, not the granted claims. Any analysis should use the 11 granted claims of US 7,668,730 B2.

Litigation / PTAB history (verified)

• CBM2014-00151 (Par Pharmaceutical, Inc. v. Jazz Pharmaceuticals) — filed July 9, 2014; not instituted (procedural).
• IPR2015-00554 (Par Pharmaceutical, Inc. and [Amneal Pharmaceuticals, LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%2C%20LLC) v. Jazz Pharmaceuticals, Inc.) — filed January 8, 2015; instituted on claims 1–11; Final Written Decision July 27, 2016 holding claims 1–11 unpatentable. Decision text: https://www.docketalarm.com/cases/PTAB/IPR2015-00554/ (and mirrored at https://ipwatchdog.com/wp-content/uploads/2018/01/730-final-written-decision.pdf).
• IPR2015-01818 (Wockhardt Bio AG et al. v. Jazz Pharmaceuticals, Inc.) — filed August 27, 2015; instituted October 30, 2015; terminated July 27, 2016 (Wockhardt settled before the Federal Circuit decision).
• Federal Circuit: Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, 895 F.3d 1347 (Fed. Cir. July 13, 2018) — affirmed the PTAB's obviousness holdings for the '730 patent and six related patents (7,765,106; 7,765,107; 7,895,059; 8,589,182; 8,457,988; 8,731,963). The dispositive issue was public accessibility of the FDA Advisory Committee materials ("ACA materials") as prior art. Opinion: https://www.govinfo.gov/content/pkg/USCOURTS-ca13-17-01675/pdf/USCOURTS-ca13-17-01675-0.pdf
• District court: Numerous cases in the District of New Jersey (e.g., 2:10-cv-06108; 2:12-cv-06761; 2:13-cv-07884; 2:14-cv-04467; 2:14-cv-07757; 2:15-cv-05619; 2:15-cv-06548; 2:17-cv-05487; 2:18-cv-00029) and one in the E.D.N.Y. (2:17-cv-04439). The '730 patent also appears in later antitrust/Orange Book actions (e.g., UFCW Local 1500 Welfare Fund v. Jazz Pharmaceuticals Ireland Ltd., N.D. Ill. 1:20-cv-03852).

CAFC 2026 dockets — explicit non-finding

I found no CAFC 2026 docket involving US 7,668,730. Targeted searches for the patent number combined with "2026," "Federal Circuit," and "appeal" returned nothing on point; the only Federal Circuit authority I could locate concerning this patent is the July 13, 2018 Jazz v. Amneal decision.

Three caveats, stated plainly because I do not want to overstate confidence:

1. I could not query the CAFC docket system or USPTO Patent Center directly. My searches surface indexed web content, not a live docket. A 2026 appeal that is very recent, sealed, or poorly indexed could exist without appearing in my results.
2. A 2026 appeal of this patent is unlikely on the merits/term. Per the authoritative record, the '730 patent is Expired – Fee Related, with adjusted expiration June 16, 2024, and its Orange Book entry carried a delist-requested flag. Its claims were cancelled in IPR2015-00554 and that cancellation was affirmed in 2018. There is no live claim scope left to litigate at the Federal Circuit in 2026 as far as the public record shows.
3. If you have a specific 2026 CAFC docket number, give it to me and I will treat that identifier literally and search against it — I will not infer or substitute a similar number.

Please treat the "no 2026 CAFC activity" conclusion as not authoritatively confirmed; everything else above is grounded in the sources cited.

I'll research litigation involving US patent 7668730. Let me run several targeted searches.

Let me search for the specific district court cases listed on the patent page.

Let me search for the Unified Patents litigation caselist filtered for this patent and for the antitrust MDL.

Litigation involving US 7,668,730 ("Sensitive Drug Distribution System and Method")

Threshold note on scope: I interpreted the patent number literally as 7,668,730 (Reardan et al., filed Dec. 17, 2002, issued Feb. 23, 2010, app. 10/322,348, originally assigned to JPI Commercial LLC / Orphan Medical, now Jazz Pharmaceuticals). I excluded results for similar but distinct numbers that appear in the same Xyrem patent family (e.g., 7,765,106; 7,765,107; 7,895,059; 8,457,988; 8,589,182; 8,731,963 and the '431/'889/'219 formulation patents). Where a case is a multi-patent Xyrem action, I flag that the '730 patent was one of several asserted patents.

Caveat up front: I could not fully verify every docket entry against PACER/CAFC within this session, and I hit a search-step limit before completing all lookups. Items below marked [UNVERIFIED DETAIL] are drawn from the patent's Google Patents "Family has litigation" listing but whose party identities I could not independently confirm. I have not fabricated parties or outcomes for those.

A. District court litigation (patent infringement / Hatch‑Waxman)

1. Jazz Pharmaceuticals, Inc. v. Ranbaxy Laboratories Ltd. (and Ranbaxy Inc.)

• Jurisdiction: D.N.J.
• Case No.: 2:14-cv-04467 (ES-JAD)
• Filing date: July 15, 2014 (Google Patents lists July 14, 2014)
• Patents: multi-patent Xyrem complaint including the '730 patent (complaint also asserted the '059, '988, '182 and '963 patents)
• Status/outcome: Closed. No reported merits judgment on the '730 patent; resolved short of trial (ANDAs of this vintage were settled/dismissed).
• Sources: Google Patents US7668730B2 litigation listing; CourtListener docket 4311738.

2. In re Xyrem (Sodium Oxybate) Antitrust Litigation — indirect purchaser/antitrust class actions citing the '730 patent
These are antitrust actions in which the '730 patent is identified as an Orange Book "REMS patent," not infringement suits:

• New York State Teamsters Council Health and Hospital Fund v. Jazz Pharmaceuticals, Inc. — N.D. Cal., 3:20-cv-04056 (Judge Richard G. Seeborg), filed June 18, 2020; patents cited include 7,668,730. Status: consolidated/part of the MDL below.
• City of Providence, Rhode Island v. Jazz Pharmaceuticals PLC — N.D. Cal., 3:20-cv-04064-LB, filed June 18, 2020; patents cited include 7,668,730.
• UFCW Local 1500 Welfare Fund v. Jazz Pharmaceuticals Ireland Ltd. — N.D. Ill., 1:20-cv-03852 (Judge Elaine E. Bucklo), filed June 30, 2020, terminated July 22, 2020 (transferred into the MDL).
• Consolidated as In re Xyrem (Sodium Oxybate) Antitrust Litigation, 3:20-md-02966-RS (N.D. Cal.).
• Outcome/status: The MDL complaint (e.g., Amended Complaint, Doc. 603, filed Mar. 15, 2024) alleges Jazz "patented its REMS processes" and that the restricted‑distribution/"REMS patents" (the '730 patent among them) were asserted to block generic entry. No final judgment on the '730 patent's validity/enforceability in this MDL that I can confirm. [UNVERIFIED DETAIL: current disposition]

3. Other D.N.J. cases in which US 7,668,730 is listed
Google Patents also lists these as family litigation, but I could not confirm plaintiff/defendant/outcome for each:

• 2:10-cv-06108 (D.N.J.) [UNVERIFIED DETAIL]
• 2:12-cv-06761 (D.N.J.) [UNVERIFIED DETAIL]
• 2:13-cv-07884 (D.N.J.) [UNVERIFIED DETAIL]
• 2:14-cv-07757 (D.N.J.) — a multi-patent Xyrem complaint (including the '730 patent); party identity not confirmed [UNVERIFIED DETAIL]
• 2:15-cv-05619 (D.N.J.) [UNVERIFIED DETAIL]
• 2:15-cv-06548 (D.N.J.) [UNVERIFIED DETAIL]
• 2:17-cv-05487 (D.N.J.) [UNVERIFIED DETAIL]
• 2:18-cv-00029 (D.N.J.) [UNVERIFIED DETAIL]

4. Eastern District of New York case listing US 7,668,730

• 2:17-cv-04439 (E.D.N.Y.) — listed on the '730 patent page as a case in which the patent is involved, but the plaintiff/defendant and nature of action are [UNVERIFIED DETAIL]; I could not confirm it is a patent-infringement case rather than a related consumer/antitrust matter.

B. PTAB proceedings (not district court, but litigation-type challenges to the '730 patent)

5. Par Pharmaceutical, Inc. v. Jazz Pharmaceuticals (IPR of U.S. 7,668,730)

• Forum: USPTO PTAB
• Case No.: IPR2015-00554
• Filed: Jan. 8, 2015; Petitioner: Par Pharmaceutical, Inc.; Patent Owner: Jazz Pharmaceuticals
• Google Patents status: Final Written Decision issued.

6. Wockhardt Bio AG v. Jazz Pharmaceuticals, Inc. (IPR of U.S. 7,668,730)

• Forum: USPTO PTAB
• Case No.: IPR2015-01818
• Filed: Aug. 27, 2015; instituted Oct. 30, 2015; Petitioner: Wockhardt Bio AG; Patent Owner: Jazz Pharmaceuticals, Inc. (assignee listed as Jazz Pharmaceuticals Ireland Ltd.)
• Panels included Judges Brian P. Murphy, Jacqueline W. Bonilla, Jon B. Tornquist, Susan L. C. Mitchell
• Status: Final Written Decision; latest docket entry July 27, 2016 (RPX Insight also tags this record as "Par Pharmaceutical v. Jazz Pharmaceuticals – IPR of '730," suggesting linkage/joinder to the Par IPRs).
• Note: A third-party compilation (usinventor.org, Nov. 2019) lists the '730 patent as PTAB: INVALID / District Court: VALID, suggesting the PTAB reached an invalidity holding while a district court found the patent valid — I state this only as reported and did not independently verify the final written decisions.

7. Par Pharmaceutical — Covered Business Method review (CBM)

• Case No.: CBM2014-00151, filed July 9, 2014; assignee at the time listed as EUSA Pharma (USA), Inc.
• Status: Not Instituted – Procedural (per Google Patents). The '730 patent is among the patents addressed in the Par/CBM cluster.

C. Related but distinct Xyrem actions I found (do not claim these assert the '730 patent without confirmation)

• Jazz Pharmaceuticals Ireland Ltd. v. Tris Pharma, Inc. (D.N.J.): the '730 patent page's litigation listing and Law360 coverage (July 8, 2026) concern a Xyrem/paper‑NDA suit; the CourtListener opinion discusses § 271(e)(2) Hatch‑Waxman pleading. I could not confirm the '730 patent is itself asserted.
• Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals — 2017 D.N.J. suit (e.g., 2:17-cv-02452) asserting the '330 patent, not the '730. Listed only to avoid conflation.
• MSP Recovery Claims, Series LLC v. Jazz Pharmaceuticals, et al. (N.D. Cal., filed Apr. 3, 2023) — RICO/state‑law pricing claims re Xyrem and Prialt; the '730 patent is not identified as asserted.

D. Bottom line

• The known, specifically-identifiable litigation activity directed at US 7,668,730 is: (i) the multi‑patent D.N.J. ANDA case Jazz v. Ranbaxy, 2:14-cv-04467, (ii) the PTAB IPR2015-00554 (Par) and IPR2015-01818 (Wockhardt), and (iii) CBM2014-00151 (Par, not instituted), plus (iv) the '730 patent's appearance in the Xyrem antitrust MDL (3:20-md-02966, N.D. Cal.) and related class actions (3:20-cv-04056; 3:20-cv-04064; 1:20-cv-03852).
• I found no CAFC appeal or reported final district‑court judgment specifically on the '730 patent within this search.
• I could not verify the parties/outcomes for the remaining D.N.J. and E.D.N.Y. case numbers listed on the patent page; those should be pulled directly from PACER before being relied on.

Primary sources used: Google Patents US7668730B2 (litigation/PTAB/assignment listings); CourtListener dockets 4311738 and the In re Xyrem MDL (3:20-md-02966, Doc. 603); RPX Insight PTAB record for IPR2015-01818; Docket Alarm PTAB records (IPR2015-00554, CBM2014-00151); drugpatentwatch.com case pages (3:20-cv-04056; 3:20-cv-04064; 1:20-cv-03852); paragraphfour.com D.N.J. complaints (14-cv-7757; 14-cv-3235; 15-cv-4532; 17-cv-2452).

If you want, I can next attempt to pull the remaining docket numbers one at a time from the Unified Patents portal caselist filtered to patent 7,668,730 to fill in the unverified party/outcome fields.

I'll start by reconciling the structured ODP block (which shows no AIA trials) against the patent-family litigation data embedded in the patent text, which lists three PTAB matters. Then I'll fill in claim-level outcomes from public sources.

Good — the patent text's litigation block names three proceedings that the ODP block missed. Let me pin down the CBM, the Wockhardt joinder, and the Federal Circuit disposition.

Now let me nail down the Wockhardt joinder/termination and the precise grounds in the '730 Final Written Decision.

PTAB Proceedings — US 7,668,730 ("Sensitive drug distribution system and method")

Data-integrity flag first. The structured "PTAB proceedings on file" block in this prompt reports no AIA trials for US 7,668,730. That block is wrong (or the ODP ingest is incomplete). The Google Patents family record embedded in the authoritative patent text for this patent explicitly lists three PTAB matters — IPR2015-01818 (Final Written Decision), IPR2015-00554 (Final Written Decision), and CBM2014-00151 (Not Instituted – Procedural) — and each is corroborated by the Board's own opinions and the CAFC opinion. I am reporting those three, with sources. I am not inventing proceeding numbers; every number below appears in the patent text's own litigation block or in a cited Board/court document.

Proceedings overview

Three AIA proceedings exist on the '730 patent — two IPRs and one CBM — with the bottom line that all 11 claims were held unpatentable in a Final Written Decision, and the Federal Circuit affirmed that judgment on 2018-07-13 (one IPR reached that FWD jointly with the parallel '988 case; the second IPR was a Wockhardt joinder that settled out before the FWD but the same FWD was entered in it; the sole CBM was never instituted because the '730 patent was held not to be a "covered business method" patent). Defensive posture: there is nothing left to assert. If a demand letter cites claims 1–11 of US 7,668,730, the claims have been canceled under 35 U.S.C. § 318(b), and the invalidity judgment is now final and affirmed — the assertion is not merely weak, it is baseless.

IPR2015-00554 — Par Pharmaceutical, Inc. and [Amneal Pharmaceuticals, LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%2C%20LLC) v. Jazz Pharmaceuticals, Inc.

• Type: Inter Partes Review (35 U.S.C. §§ 311–319)
• Filed: 2015-01-08
• Status: Final Written Decision — FWD entered 2016-07-27; claims 1–11 (all claims) unpatentable. Request for rehearing denied 2016-12-22 (Paper 72). Family record now shows Expired - Fee Related.
• Judge panel: Jacqueline Wright Bonilla, Brian P. Murphy, Jon B. Tornquist. Opinion authored by Murphy, APJ.
• Petition grounds: obviousness under § 103(a) over the "Advisory Committee Art" ("ACA") — four FDA advisory-committee documents (Exs. 1003–1006): the FDA Peripheral & Central Nervous System Drugs Advisory Committee Transcript and Slides (2001-06-06), the FDA Preliminary Clinical Safety Review of NDA 21-196 (2001-05-03), the Xyrem® Briefing Booklet (2001-05-03), and the Xyrem® prescription/distribution-process Video and Transcript (2001-02-01). Claims 1–11 challenged — i.e., every claim, including independents 1, 2, 7, 8, 9, 10, 11 and dependents 3, 4, 5, 6.
• Institution decision: Instituted, 2015-07-28 (Paper 20). The Board found a reasonable likelihood of prevailing and instituted on all claims 1–11 of the '730 patent (and claims 1–15 of the related '988 patent), but — as the Federal Circuit later noted — "instituted review on fewer than all grounds raised in the petition." Jazz's § 315(b) timeliness / real-party-in-interest challenge (arguing Par's parent entities were undisclosed RPIs) was briefed and rejected.
• Final Written Decision: 2016-07-27 (Paper 68). Verbatim disposition: "For the reasons that follow, we determine Petitioner has shown by a preponderance of the evidence that claims 1–11 of the '730 patent and claims 1–15 of the '988 patent are unpatentable." All claims canceled — no claim survived. Key panel reasoning: the ACA materials were "printed publication" prior art under pre-AIA § 102(b) because a POSA "would have been familiar with the Federal Register and motivated to look for notices related to drug distribution, safety, or abuse prevention," and would have been able to locate the June 6, 2001 advisory-committee materials on the FDA website by at least 2001-10-04 — more than a year before the 2001-12-17 critical date. The panel also construed "periodic reports" as "reports that are generated at regular intervals or intermittently" (rejecting Jazz's narrower "regular frequencies only" reading) and construed "information identifying patients." Petitioner's motions to exclude/late-file evidence were dismissed as moot. A combined oral hearing covering IPR2015-00545, -00546, -00547, -00548, -00551 and -00554 was held 2016-04-19.
• Settlement / termination: None as to Par/Amneal — they litigated to FWD and appeal. (However, co-petitioner-by-joinder Wockhardt was terminated from the related proceedings on 2016-05-05; see below.)
• Appeal: Yes. Jazz appealed; the appeal was consolidated with six others as Nos. 2017-1671, -1673, -1674, -1675, -1676, -1677, and -2075 (Fed. Cir.), decided 2018-07-13. Reported as Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, 895 F.3d 1347 (Fed. Cir. 2018), panel of Newman, Lourie, Reyna; opinion by Lourie, J. Affirmed. The court held that substantial evidence supported the Board's finding that the ACA materials were publicly accessible printed publications; expressly declined to impose an indexing/searchability requirement on printed publications; and affirmed the obviousness judgment. Link: https://www.courtlistener.com/opinion/[4516711](/patent/4516711)/jazz-pharmaceuticals-inc-v-amneal-pharmaceuticals-llc/
• Defensive value: Decisive for a defendant. Claims 1–11 are canceled and the invalidity judgment is final after a Federal Circuit affirmance. Any infringement theory built on this patent is dead; a demand letter citing it is not merely weak but exposing to Rule 11 / § 285 risk. The FWD is the dispositive document to attach to any response: https://www.docketalarm.com/cases/PTAB/IPR2015-00554/Inter_Partes_Review_of_U.S._Pat._7668730/docs/07-27-2016-Board/Final_Decision-68-Final_Written_Decision.pdf (mirror: https://ipwatchdog.com/wp-content/uploads/2018/01/730-final-written-decision.pdf).

IPR2015-01818 — Wockhardt Bio AG (et al.) v. Jazz Pharmaceuticals, Inc.

• Type: Inter Partes Review (filed with a Motion for Joinder to IPR2015-00554)
• Filed: 2015-08-27
• Status: Final Written Decision (a copy of the IPR2015-00554 FWD was entered in this docket on 2016-07-27); the proceeding itself was terminated as to Petitioner Wockhardt Bio AG on 2016-05-05 on the parties' joint request following settlement. Public posture: settlement-terminated joinder; no independent claim-level adjudication beyond the copied FWD.
• Judge panel: Brian P. Murphy, Jacqueline Wright Bonilla, Jon B. Tornquist, Susan L. Mitchell (per docket); institution + joinder granted by the same panel that decided -00554 (Paper 37).
• Petition grounds: § 103(a) — substantively an "almost verbatim copy" of the IPR2015-00554 petition, directed at claims 1–11 of the '730 patent over the same ACA prior art (Wockhardt Exhibits 1001–1032, including Ex. 1007 Valuck Declaration and the same ACA exhibits, plus Wayback Machine evidence of ACA accessibility). Wockhardt's stated goal was not a new invalidity theory but joinder into the Amneal/Par trial.
• Institution decision: Instituted, 2015-10-30, and Motion for Joinder granted (Paper 37) — Wockhardt was joined into IPR2015-00554 in relation to the '730 patent.
• Final Written Decision: The same 2016-07-27 Paper 68 FWD was entered in this docket, reaching claims 1–11 unpatentable. Caveat: because the proceeding had already been terminated as to Wockhardt on 2016-05-05, that entry had no independent claim-level effect — the operative findings are those of IPR2015-00554. I flag this rather than characterize the -01818 FWD as a separate adjudication.
• Settlement / termination: Yes — Jazz and Wockhardt entered a confidential settlement agreement dated 2016-04-18, together with a license for Wockhardt to market a generic sodium oxybate "on or after December 31, 2025, or earlier depending on the occurrence of certain events." On the parties' joint motion, the Board terminated the proceedings as to Wockhardt on 2016-05-05 (Paper 11 in -01818; Paper 66/68 in the joined cases) and granted the request to treat the settlement agreement as business confidential information under 37 C.F.R. § 42.74(c). The terms are confidential. Wockhardt also withdrew from the related appeals (Duane Morris, which represented Wockhardt, noted Wockhardt "settled its case prior to the Federal Circuit decision").
• Appeal: None by Wockhardt (settled out). The underlying invalidity judgment was appealed by Patent Owner Jazz and affirmed in the consolidated 2017-1671 appeal described above.
• Defensive value: Neutral-to-favorable. Wockhardt's joinder shows the ACA-based § 103 theory was strong enough to attract a second, independent challenger willing to copy the petition verbatim — a useful corroboration signal. But nothing in -01818 creates relief beyond what IPR2015-00554 already delivered.

CBM2014-00151 — Par Pharmaceutical, Inc., Roxane Laboratories, Inc. and Amneal Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc.

• Type: Covered Business Method review (AIA § 18; 35 U.S.C. § 321)
• Filed: 2014-07-09
• Status: Not Instituted - Procedural — Decision Denying Institution of Covered Business Method Patent Review, 2015-01-13.
• Judge panel: Lora M. Green, Brian P. Murphy, Jon B. Tornquist; opinion authored by Murphy, APJ.
• Petition grounds: claims 1–11 unpatentable under § 101, § 102(b) and § 103(a).
• Institution decision: Denied — 2015-01-13. The Board held that Petitioner had not demonstrated that the '730 patent is a "covered business method patent" within AIA § 18(d)(1). It therefore never reached the merits of the § 101/§ 102/§ 103 grounds. The decision was issued jointly across CBM2014-00149 ('059), -00150 ('988), -00151 ('730), and -00153 ('182), and the Board noted that institution was denied in all six CBM cases in the Xyrem family (including CBM2014-00161 ('106) and -00175 ('107)). Decision text: https://ptabtrialblog.com/wp-content/uploads/2015/01/CBM2014-00149-150-151-153-Denying-Institution-of-Cover-Business-Method-Review-20150113.pdf
• Final Written Decision: None — no trial was instituted.
• Settlement / termination: N/A.
• Appeal: None. Denials of institution are not appealable.
• Defensive value: Little independent value today; the CBM path was foreclosed on the § 18(d)(1) jurisdictional question, not on the merits. Its historical significance is that it explains why Jazz's challengers pivoted to IPR on prior-art grounds — and won there.

Strategic summary

Claim status. Every claim of US 7,668,730 — claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11 — is CANCELED as a result of the IPR2015-00554 Final Written Decision (2016-07-27), with no independent or dependent claim sustained and no claim untested. The Board's determination was that "claims 1–11 of the '730 patent … are unpatentable," and the Federal Circuit affirmed on 2018-07-13 (895 F.3d 1347). The Google Patents record classifies the patent as Expired - Fee Related, with an adjusted expiration of 2024-06-16; that maintenance-fee status is moot given the invalidity judgment. There is no surviving claim to assert. If someone is threatening enforcement of the '730 patent, the correct response is the FWD plus the CAFC mandate, not a validity fight.

Estoppel landscape. In the abstract, § 315(e)(2) estops Par Pharmaceutical, Amneal Pharmaceuticals, Wockhardt Bio AG, Wockhardt Limited, Wockhardt USA LLC, Morton Grove Pharmaceuticals, Inc. and MGP Inc., and their privies, from raising in a civil action any ground they raised or reasonably could have raised in the IPRs (and § 315(e)(1) bars the same grounds in later IPR/PGR petitions). The Par parents that Jazz argued were undisclosed RPIs (Par Pharmaceutical Companies, Sky Growth Intermediate Holdings I and II) could be swept into that estoppel net had the RPI argument succeeded. Practically, the estoppel question is academic: with the claims canceled under § 318(b), there is no patent to assert and no ground a defendant needs to preserve. The relevant residual exposure is the opposite direction — Patent Owner Jazz is collaterally estopped from relitigating patentability of these claims. Note also that the '730 patent's challenged claims were the entire claim set, so there is no partial-narrowing residue.

Pattern signals. (1) Same-petitioner clustering: Par/Amneal filed a coordinated six-IPR attack on the family ('545, '546, '547, '548, '551, '554) plus a parallel six-CBM sweep that was denied institution across the board for lack of CBM eligibility. (2) Follow-on copier: Wockhardt filed six copycat IPR petitions in Aug–Dec 2015 (IPR2015-01813/01814/01815/01816/01818/01820) each with a motion to join the corresponding Amneal/Par trial — IPR2015-01818 being the '730 matter. This is a generics-versus-generics race to judgment, not a defensive aggregator. Important nuance: Unified Patents appears in this record only as the source of the PTAB litigation metadata in the patent text — Unified Patents is not a petitioner here. Reading the patent text's "PTAB case … filed" entries as Unified Patents filings would be an error. (3) Patent owner appealed aggressively and lost: Jazz consolidated seven Federal Circuit dockets (2017-1671, -1673, -1674, -1675, -1676, -1677, -2075), sought panel rehearing at the Board (denied 2016-12-22), and ultimately accepted the outcome. The net family effect was mass invalidation: the Board found the claims of six REMS patents unpatentable in July 2016, and the seventh ('963) was partially instituted in March 2016 with an FWD in March 2017 (later affected by SAS Institute v. Iancu, 138 S. Ct. 1348 (2018), on partial institution). Jazz's own SEC filings concede that if the CAFC upheld the PTAB decisions, "we will not be able to enforce claims the PTAB found unpatentable."

One caution for cross-checking family members. Sibling continuations from the same 2002-12-17 priority date are not all in the same posture. For example, the Google Patents family table shows US 7,797,171 as Active with expiration 2026-07-19 and US 8,731,963 as Expired - Lifetime. Do not assume the '730 invalidity judgment automatically transfers; separate patents require separate FWD/CAFC analysis. (The '963 patent's later Federal Circuit appearance, Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC, No. 2023-1186 (Fed. Cir. Feb. 24, 2023), concerns Orange Book listing of system claims as method-of-use claims under 21 U.S.C. § 355 and 21 C.F.R. § 314.53(b)(1) — it is not a validity holding and is not a proceeding on the '730 patent.)

Recommended next steps

1. If you are a defendant and received a demand or complaint citing US 7,668,730: link and attach the IPR2015-00554 Final Written Decision (2016-07-27) and the Federal Circuit affirmance (Jazz Pharm., Inc. v. Amneal Pharm., LLC, 895 F.3d 1347 (Fed. Cir. 2018), 2018-07-13). Quote the disposition verbatim: "we determine Petitioner has shown by a preponderance of the evidence that claims 1–11 of the '730 patent and claims 1–15 of the '988 patent are unpatentable." Then request confirmation of whether the USPTO has issued the certificate of cancellation under § 318(b). Since the appeal is long final, it should have issued; verify in Patent Center before responding formally.
2. Check what is actually being asserted. Because all '730 claims are gone, any live threat must rest on a different patent in the Xyrem/Xywav family (e.g., the still-Active US 7,797,171, or later REMS/continuation patents such as those in the US 11,456,081 line) or on non-patent rights. The Avadel/'963 Orange-Book-listing decision is the most likely adjacent battlefield — treat it as a separate matter, not as a '730 proceeding.
3. No PTAB trial-stage milestones to track for this patent. There are no pending IPRs, PGRs or CBMs on the '730 patent, so there is no institution-deadline, oral-hearing or § 316(a)(11) one-year FWD clock running. If you learn of a newly filed petition against the '730 patent, treat it with skepticism: the claims are already finally canceled, so a new petition would be procedurally anomalous (and likely barred/pointless). Re-verify via USPTO PTAB E2E / the Open Data Portal before relying on this — and note again that the ODP block supplied with this task was demonstrably incomplete for this patent.
4. If you are the patent owner or a licensee: there is no viable enforcement path on the '730 patent. Any valuation or damages model built on it should be written down to zero.

Confidence and gaps. High confidence on: the existence of the three proceedings, the petitioners/patent owner, the IPR2015-00554 institution date (2015-07-28) and FWD date (2016-07-27), the all-claims-unpatentable outcome, the judge panels, the § 103(a)/ACA grounds, the CAFC affirmance on 2018-07-13 at 895 F.3d 1347, the CBM denial on § 18(d)(1) grounds (2015-01-13), and the Wockhardt settlement/termination (2016-05-05). Lower confidence / explicitly flagged: (a) the precise mechanics of the FWD entry in IPR2015-01818 after Wockhardt's termination; (b) the Board's exact construction of "information identifying patients" and precisely how the CAFC treated each construction — I have not verified that sentence-by-sentence against the slip opinion. If you need those two points nailed down for a filing, pull the full text of Paper 68 (IPR2015-00554) and the 2017-1671 opinion from PTAB E2E and the CAFC docket respectively.

I'll start by pulling what I can from the assignment/legal-events record and cross-referencing ownership history for this patent.

Good — I found two recorded assignments. Let me pull the rest of the chain from the assignment indexes.

Let me try to locate the later links in the chain and the security-interest recordings.

Ownership reconstruction — US 7,668,730 B2 ("Sensitive drug distribution system and method")

Source note / methodology caveat. I do not have a live authenticated session against Assignment Center, so the reel/frame confirmations below come from (a) the USPTO assignment records as mirrored by PlainSite's assignment.html pages, and (b) the Google Patents "reassignment / legal events" table for US 7,668,730 and its family. I was able to confirm two reel/frame records with correspondent data; for the 2008–2021 corporate and security recordings I have the conveyance type, assignor, assignee and recording date from Google Patents legal events but not the reel/frame or the correspondent of record. Where that is the case I say so rather than guess. Verify at https://assignment.uspto.gov/patent/index.html and https://assignmentcenter.uspto.gov/.

Inventors

Employer is not stated on the face of the patent, but it is determinable from the chain: all three executed assignments of their entire interest to Orphan Medical, Inc. within ~5 months of the 2002-12-17 filing (Reel 14105/0873, recorded 2003-05-27; individually executed Reardan 2003-04-03, Gagne 2003-05-01, Engel 2003-05-13). That is a standard obligation-to-assign pattern for employees/consultants of the applicant, and all three are Minnesota-resident, consistent with Orphan Medical's Minnetonka headquarters.

Unusual patterns: none of the fire-sale tells apply here. Inventor-to-company assignment was prompt (≈5 months), not late, and the same three inventors persist across the entire continuation/divisional family (US 7,765,106; 7,765,107; 7,797,171; 7,895,059; 8,731,963; 8,457,988; 8,589,182), which is consistent with an operating company prosecuting its own platform rather than a team dispersing. I could not verify actual employment-departure dates for any inventor — that is a data gap, not a finding. One clerical artifact worth noting: the 2003 recordation spells the second inventor "Engle, Patti," while the 2004-01-12 recordation and the patent itself use the correct "Engel, Patti A."

Original assignee

Orphan Medical, Inc. (Minnetonka, MN) receives the inventors' assignment by Reel 14105/0873. Orphan Medical was a publicly traded specialty pharmaceutical company whose principal business was the development and commercialization of Xyrem® (sodium oxybate oral solution) for cataplexy in narcolepsy. The patent claims the restricted-distribution architecture — exclusive central pharmacy, exclusive database, prescriber credentialing, patient education verification, mailing and receipt confirmation — i.e., the very system Orphan Medical actually operated (the "Xyrem Success Program"). This is a product-embodying patent family, not a paper asset.

Status history:

• Orphan Medical, Inc. was acquired by Jazz Pharmaceuticals, Inc. via merger with Twist Merger Sub, Inc. — "Agreement and Plan of Merger dated as of April 18, 2005" is listed as Exhibit 2.1 to Jazz's 2009 Form 10-K (https://app.stocklight.com/stocks/us/nasdaq-jazz/jazz-pharmaceuticals/annual-reports/nasdaq-jazz-2009-10K-091236659.pdf). Orphan Medical thereupon became an indirect subsidiary; it was later merged into Orphan Medical, LLC (Reel 23964/0365, executed 2008-03-14, recorded 2010-02-19).
• In 2007 Orphan Medical, Inc. entered civil settlement / non-prosecution agreements with the U.S. Attorney for the Eastern District of New York (Exhibits 10.21A/10.21B to Jazz's 10-K) — a marketing-compliance matter, not a bankruptcy.
• No bankruptcy, no dissolution, no Chapter 7/11 sale. Orphan Medical's assets passed to Jazz through a stock merger, not a distress sale. Apple-to-apple, this is the opposite of a Kodak/Nortel fire-sale posture.

Note a data inconsistency to verify on the record: Google Patents lists the original assignee as "JPI Commercial LLC" and the current assignee as "Jazz Pharmaceuticals Inc." for US 7,668,730, while the inventors' chain-of-title unambiguously begins at Orphan Medical, Inc. The "JPI Commercial LLC" entry reflects a post-issuance holding-subsidiary arrangement, not the originating applicant.

Assignment timeline

Chronological, as recorded. Reel/frame shown only where confirmed.

• 2003-05-27 (executed 2003-04-03 Reardan, 2003-05-01 Gagne, 2003-05-13 Engel) / recorded 2003-05-27 — Reel 14105/0873

  • Conveyance: Assignment (Assignment of Assignors' Interest)
  • Assignor: Reardan, Dayton T.; Engel, Patti; Gagne, Bob
  • Assignee: Orphan Medical, Inc., 13911 Ridgedale Drive, Suite 475, Minnetonka, MN 55305
  • Correspondent: Bradley A. Forrest, Schwegman, Lundberg & Woessner, P.A., P.O. Box 2938, Minneapolis, MN 55402. Recurrence flag: Schwegman, Lundberg & Woessner is also the "Attorney, Agent, or Firm" of record on the family members (e.g., US 7,765,107 per uspto.report) — i.e., this is the operating company's prosecution firm recurring across the family, not an NPE recording agent.
  • Context: initial employment/obligation assignment to the operating applicant.
  • Source: https://www.plainsite.org/patents/assignment.html?id=[2614483](/patent/2614483)

• 2004-01-12 / recorded 2004-01-12 — Reel/frame not retrieved

  • Conveyance: Assignment ("Assigned to ORPHAN MEDICAL, INC.")
  • Assignor: Engel, Patti; Gagne, Bob; Reardan, Dayton T.
  • Assignee: Orphan Medical, Inc.
  • Correspondent: not retrieved
  • Context: almost certainly a confirmatory re-recording (the name is spelled correctly "ENGEL" here versus "ENGLE" in 14105/0873) timed to the first divisional filings — inference, not confirmed by the instrument itself.

• 2005-07-29 / recorded 2005-07-29 — Reel/frame not retrieved

  • Conveyance: Security Interest
  • Assignor: Twist Merger Sub, Inc.
  • Assignee: LB 1 Group Inc.
  • Correspondent: not retrieved
  • Context: acquisition financing tied to the 2005 Orphan Medical merger (Twist Merger Sub was Jazz's merger vehicle). LB I Group is affiliated with Lehman Brothers Holdings Inc. — creditor, not a purchaser of the patent.
  • Source: Google Patents legal events for US 7,668,730.

• 2008-04-04 / recorded 2008-04-04 — Reel/frame not retrieved

  • Conveyance: Security Agreement
  • Assignor: JPI Commercial, LLC
  • Assignee: LB I Group Inc.
  • Correspondent: not retrieved
  • Context: securitization. Collateral pledge securing the ~$120M March 2008 JPI Commercial senior secured notes (Jazz 10-K: "JPI Commercial, LLC, or JPIC, a wholly-owned subsidiary of Jazz Pharmaceuticals"); the noteholders were LB I Group and KFN.

• executed 2008-03-14 / recorded 2010-02-19 — Reel 23964/0365

  • Conveyance: Merger
  • Assignor: Orphan Medical, Inc.
  • Assignee: Orphan Medical, LLC
  • Correspondent: not retrieved (PlainSite record shows no correspondent line)
  • Context: internal corporate reorganization (Inc. → LLC conversion).
  • Source: https://www.plainsite.org/patents/assignment.html?id=[4745916](/patent/4745916)

• 2010-02-19 / recorded 2010-02-19 — Reel/frame not retrieved

  • Conveyance: Assignment
  • Assignor: Orphan Medical, LLC
  • Assignee: Jazz Pharmaceuticals, Inc.
  • Correspondent: not retrieved
  • Context: internal reorganization; recorded 4 days before the 2010-02-23 grant.

• 2010-02-23 — patent granted (US 7,668,730 B2).

• 2010-06-30 / recorded 2010-06-30 — Reel/frame not retrieved

  • Conveyance: Security Agreement — Assignor Jazz Pharmaceuticals, Inc. → Assignee Silicon Valley Bank
  • Context: venture-debt collateral pledge.

• 2010-06-30 / recorded 2010-06-30 — Reel/frame not retrieved

  • Conveyance: Release by Secured Party — Assignor LB I Group, Inc. → Assignee JPI Commercial, LLC
  • Context: retirement/release of the 2008 security interest.

• 2010-11-12 (two entries) / recorded 2010-11-12 — Reel/frame not retrieved

  • Conveyance: Assignment — Orphan Medical, LLC → JPI Commercial, LLC
  • Conveyance: Merger — Orphan Medical, Inc. → Orphan Medical, LLC
  • Context: internal reorganization; duplicate recording across family members.

• 2010-11-17 / recorded 2010-11-17 — Reel/frame not retrieved

  • Conveyance: Assignment — JPI Commercial, LLC → Jazz Pharmaceuticals, Inc.
  • Context: intra-group standing cleanup executed ~5 days before the first infringement complaint (Jazz v. Roxane, D.N.J. 2:10-cv-06108, complaint filed 2010-11-22).

• 2010-11-26 (two entries) / recorded 2010-11-26 — Reel/frame not retrieved

  • Conveyance: Merger — Orphan Medical, Inc. → Orphan Medical, LLC
  • Conveyance: Assignment — Orphan Medical, LLC → JPI Commercial, LLC
  • Context: internal reorganization; duplicate recording.

• 2010-12-22 / recorded 2010-12-22 — Reel/frame not retrieved

  • Conveyance: Assignment — JPI Commercial, LLC → Jazz Pharmaceuticals, Inc.
  • Context: completion of the same intra-group movement to the litigating parent.

• 2011-12-30 / recorded 2011-12-30 — Reel/frame not retrieved

  • Conveyance: Release — Silicon Valley Bank → Jazz Pharmaceuticals, Inc. Context: debt payoff.

• 2012-08-06 / recorded 2012-08-06 — Reel/frame not retrieved

  • Conveyance: Security Interest — EUSA Pharma (USA), Inc.; Jazz Pharmaceuticals International Limited; Jazz Pharmaceuticals, Inc. → Barclays Bank PLC, as collateral agent
  • Context: securitization (post-2012 Jazz/EUSA credit facility).

• 2015-06-19 / recorded 2015-06-19 — Reel/frame not retrieved

  • Conveyance: Security Agreement — Jazz Pharmaceuticals International III Ltd.; Jazz Pharmaceuticals International Ltd.; Jazz Pharmaceuticals Ireland Ltd.; Jazz Pharmaceuticals, Inc. → Bank of America, N.A., as collateral agent
  • Context: securitization (refinancing).

• 2015-07-09 / recorded 2015-07-09 — Reel/frame not retrieved

  • Conveyance: Release by Secured Party — Barclays Bank PLC → Jazz entities. Context: prior lien released.

• 2021-05-05 / recorded 2021-05-05 (two entries) — Reel/frame not retrieved

  • Conveyance: Security Agreement — Cavion, Inc.; Celator Pharmaceuticals, Inc.; Jazz Pharmaceuticals Ireland Ltd.; Jazz Pharmaceuticals, Inc. → U.S. Bank National Association
  • Conveyance: Release by Secured Party — Bank of America, N.A. → Jazz entities
  • Context: securitization refinancing.

No assignment in this chain is a sale of the patent away from the Jazz corporate group. Every instrument after 2008 is either an intra-group reorganization or a lender's collateral interest/release.

Timeline diagram

timeline
    title Ownership of US 7668730
    2002 : Application filed 17 Dec
    2003 : Inventors assign to Orphan Medical
    2004 : Confirmatory assignment recorded
    2005 : Orphan Medical acquired by Jazz
    2008 : Merger into Orphan Medical LLC
         : JPI Commercial pledge to LB I Group
    2010 : Patent issued 23 Feb
         : JPI Commercial to Jazz Pharmaceuticals
         : Jazz sues Roxane over Xyrem
    2012 : Barclays collateral security interest
    2015 : Generic IPR petitions filed
    2021 : US Bank collateral security agreement
    2024 : Patent expires

NPE / troll-pattern signals

1. Shell-entity transfer — not present. No operating-to-licensing-only transfer. The 2010 flurry moves the patent within the Jazz group (Orphan Medical, Inc. → Orphan Medical, LLC → JPI Commercial, LLC → Jazz Pharmaceuticals, Inc.). "JPI Commercial, LLC" carries an LLC suffix but is documented in SEC filings as "a Delaware limited liability corporation and wholly-owned subsidiary of Jazz Pharmaceuticals, Inc." (Solvay License Agreement amendments, Exhibits 10.77–10.79 to Jazz's 10-K). It also executed product-rights transactions in its own name (Antizol product-rights acquisition, Aug 2008; LUVOX CR license from Solvay), so it is a product-rights/holding entity, not a bare licensing shell. Reel 23964/0365 (2010-02-19 merger) is the only confirmed reel/frame link in this segment.

2. Known asserter in the chain — not present. No assignee matches Acacia, Marathon, IV, IPNav, Wi-LAN, Conversant/Mosaid, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, DOC, or any Spangenberg entity. Current assignee of record: Jazz Pharmaceuticals, Inc. The asserted patents in this family were enforced in Jazz's own name (Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc., D.N.J. 2:10-cv-06108, complaint 2010-11-22; v. [Amneal Pharmaceuticals LLC](/litigations/by-plaintiff/Amneal%20Pharmaceuticals%20LLC), 2:13-cv-00391 — the AO 120 filing names "JAZZ PHARMACEUTICALS, INC." as plaintiff).

3. Repeat correspondent across the chain — not present as an NPE tell (with a completeness caveat). The single confirmed correspondent is Bradley A. Forrest, Schwegman, Lundberg & Woessner, P.A., Minneapolis on Reel 14105/0873 (2003-05-27). Schwegman also appears as the attorney/agent firm on family member US 7,765,107, so the firm does recur — but it is the operating company's prosecution firm handling its own portfolio, which is the opposite pattern from a single lawyer running a stable of unrelated shell LLCs. Correspondents for the 2008–2021 corporate/security recordings were not retrievable in this pass, so I cannot assert whether one firm recorded all of them.

4. Cascading transfers — present in form, not in substance. Between 2010-02-19 and 2010-12-22 there are at least seven recorded instruments (two mergers, at least three assignments, plus releases), and 2010-11-12 and 2010-11-26 each show the same Orphan Medical, LLC → JPI Commercial, LLC pair recorded twice. That cadence looks like a cascade on its face, but the assignors/assignees are all within one corporate group with a common parent, the duplicate entries correspond to recordation against multiple family members, and the terminus is the operating parent. I score this not present as an NPE signal, while noting the volume of recordings is unusually high for a simple reorganization.

5. Pre-litigation transfer — present as to timing. The 2010-11-17 assignment of the family from JPI Commercial, LLC to Jazz Pharmaceuticals, Inc. was recorded five days before the 2010-11-22 Roxane complaint, with a further 2010-12-22 assignment of the same pair. That is squarely within the "≤6 months before first suit" window and is consistent with standing/venue cleanup. Critically, though, the transferee is the operating parent that markets Xyrem, not a litigation vehicle — so the timing is a standing-hygiene finding, not a troll signal.

6. Bankruptcy fire-sale — not present. No Chapter 7/11 of Orphan Medical or Jazz. Orphan Medical was acquired in a 2005 stock merger (Agreement and Plan of Merger dated 2005-04-18, Exhibit 2.1 to Jazz's 2009 10-K). Its 2007 EDNY agreements were compliance settlements, not insolvency events.

7. Privateering — not present on the evidence. Jazz did not hand the patent to a third-party asserter to sue on its behalf. Jazz sued ANDA filers in its own name, and where third parties appear in the record they appear as licensees/debt holders, not enforcers: JPI Commercial licensed Xyrem-adjacent rights to UCB Pharma (Xyrem License and Distribution Agreement) and to Solvay Pharmaceuticals (LUVOX CR), and the security interests run to LB I Group, Silicon Valley Bank, Barclays, Bank of America, U.S. Bank — all creditors. No Patent Progress / EFF privateering coverage appears in this chain.

8. Defensive aggregator — not present. The chain terminates at Jazz Pharmaceuticals, Inc. (current assignee per Google Patents); it does not end at RPX, AST, LOT, Unified Patents, or OIN. Inverse signal does not apply.

Corroborating context (operating-company, not NPE): the '730 patent is Orange Book–listed for sodium oxybate (Xyrem), with a listed expiry of June 16, 2024 (plus pediatric extension to December 16, 2024) per the Orange Book, and Google Patents shows a status of "Expired – Fee Related, expires 2024-06-16." The same family was attacked by generic petitioners, not by Jazz: IPR2015-00554 (Amneal Pharmaceuticals LLC, Par Pharmaceuticals, Inc., Wockhardt Bio AG v. Jazz Pharmaceuticals, Inc., patent 7,668,730, Final Written Decision) and IPR2015-01818 (Wockhardt Bio AG v. Jazz), plus CBM2014-00151 (not instituted, procedural). Jazz also filed ten district-court actions in D.N.J. (2:10-cv-06108; 2:12-cv-06761; 2:13-cv-07884; 2:14-cv-04467; 2:14-cv-07757; 2:15-cv-05619; 2:15-cv-06548; 2:17-cv-05487; 2:18-cv-00029) and one in E.D.N.Y. (2:17-cv-04439) — a brand-vs-generic campaign, not an NPE assertion program.

Verdict

Operating-company assertion.

The ownership chain runs from the three inventors through Reel 14105/0873 (2003-05-27) to Orphan Medical, Inc., the company that actually commercialized Xyrem and operated the restricted-distribution program the claims recite, and then via the 2005 Jazz merger and Reel 23964/0365 (2010-02-19) plus the 2010 intra-group recordings into Jazz Pharmaceuticals, Inc., which still owns it. Every post-2008 instrument is either an internal reorganization or a lender's collateral interest/release (LB I Group 2008-04-04; Silicon Valley Bank 2010-06-30; Barclays 2012-08-06; Bank of America 2015-06-19; U.S. Bank 2021-05-05), and none of the eight NPE signals is present on the evidence. The patent was enforced by the operating owner in its own name against ANDA-filing competitors (Roxane 2010, Amneal 2013, Par/Wockhardt IPRs 2015) on an Orange Book–listed product, which is the textbook operating-company posture — with the one notable housekeeping detail that the ownership was consolidated into the litigating parent on 2010-11-17, five days before the first complaint.

Verify the chain at: https://assignment.uspto.gov/patent/index.html (search "7668730") and https://assignmentcenter.uspto.gov/; the two confirmed reel/frame records are mirrored at https://www.plainsite.org/patents/assignment.html?id=2614483 (14105/0873) and https://www.plainsite.org/patents/assignment.html?id=4745916 (23964/0365).

I'll research this patent and its prior art citations. Let me start with targeted searches.

Let me gather more detail on the key cited references and the PTAB proceedings that challenged this patent.

Prior Art Analysis — US 7,668,730 B2

⚠️ Scope note before the analysis

• Patent confirmed: US 7,668,730 B2, "Sensitive drug distribution system and method," inventors Dayton T. Reardan, Patti A. Engle (recorded as "Engle"/"Engel"), Bob Gagne; App. No. 10/322,348; filed 2002‑12‑17; granted 2010‑02‑23; assignee Jazz Pharmaceuticals Inc. (originally JPI Commercial LLC). Status per the record: Expired – Fee Related (adjusted expiration 2024‑06‑16). Source: https://patents.google.com/patent/US7668730/en
• Claims at issue: 11 claims. Independent claims 1, 2, 7, 8, 9, 10, 11; dependent claims 3–6.
• Critical honesty caveat on § 102 vs. § 103: I could not verify that any single cited reference was actually applied as a standalone anticipation under § 102. The prosecution history shows the examiner relied principally on § 103 obviousness combinations (e.g., Moradi, Lilly, Mayaud, Evans, Akers, Williams/Celgene, Kapp, Reitberg). Below I identify which claims each reference is most relevant to and could arguably reach under § 102, but I flag that these were § 103 art in practice. I did not independently re-verify every publication date; dates are drawn from the patent's own "References Cited" list and search results, with uncertain items flagged.
• Applicable § 102 regime: Because the application was filed 2002‑12‑17, pre‑AIA § 102 governs. Thus only references that are § 102(a)/(b)/(e) art (i.e., publicly available, or with a US filing date, before the critical date) can anticipate. Several cited references published in 2003–2004 (e.g., US 2004/0019794 Moradi) can only reach § 102(e) art if their underlying US filing predates the applicant's date — they cannot be § 102(b) art.

The gatekeeping limitation that defeated all § 102 anticipation

Every independent claim requires that all prescription requests for the drug be received only at a single exclusive central pharmacy and processed using only the exclusive computer database, with "use of the exclusive computer database ... required for distribution." In the appeal/interview history the applicant expressly distinguished the art on this basis:

"This differs significantly from Moradi et al., which selects a pharmacy based on the patient's location... Lilly describes cooperative use of a database by multiple pharmacies... None of the references, alone or combined, suggest that a sensitive drug can only be distributed under control of a single source, or required to be tracked through the use of a single central database."

No cited reference discloses that exclusivity-of-source element, which is why no reference anticipated and the claims ultimately issued. Source (file history excerpt): https://www.docketalarm.com/cases/PTAB/IPR2015-00547/

The cited prior art (References Cited on the face of the patent)

The "References Cited" list for this family (confirmed via the sibling patent text at http://euro.ecom.cmu.edu/people/faculty/mshamos/[7765106](/patent/7765106).pdf) is reproduced below with my § 102 relevance assessment. US patents:

Published US applications cited (per the same list; publication dates as listed, with hard-to-read items flagged):

Non‑patent literature cited (all pre‑filing → § 102(b) art):

• NASCSA National Conference (Nov 2000), 8 pp.
• "Diversion Prevention Through Responsible Distribution," NADDI Regional Training (May 2001; Tennessee, Jun 2001; National Conference, Nov 2001).
• FDA Peripheral & Central Nervous System Drugs Advisory Committee, Bethesda, MD (Jun 6, 2001) — directly relevant to the Xyrem/GHB context.
• "System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.) Starter Kit," Celgene Corp. (2001), 103 pp. — highly probative of the education/registry/restricted‑distribution concept.
• Ukens, "Specialty Pharmacy," Drug Topics 144 (Jun 5, 2000), 40–47.
• "An Interview with Orphan Medical about Xyrem," talkaboutdeep.com (Feb 12, 2001) — applicant‑side publicity; relevant to on‑sale/public‑use § 102(b) considerations.

Bottom line

1. Most relevant prior art (ranked): (a) Celgene/Williams family — US 6,315,720; US 6,045,501; US 6,561,977; US 6,755,784; plus the S.T.E.P.S. Starter Kit (2001); and (b) Mayaud US 5,845,255 / US 2002/0042725 (abuse‑monitoring prescription database). These map onto independent claims 1, 2, 7, 11 element‑by‑element except for the "exclusive central pharmacy / exclusive database required for distribution" limitation.
2. Claims 8–10 (GHB‑specific) add only the drug identity; the same references plus the June 2001 FDA Advisory Committee material and the Feb 2001 Orphan Medical interview touch GHB/Xyrem directly.
3. No reference anticipates under § 102 as issued. The examiner's actual rejections were § 103 combinations (notably Moradi + Lilly, and Mayaud/Evans/Akers/Kapp/Reitberg), and the applicant obtained allowance by arguing that none taught or suggested single‑source exclusivity of the pharmacy and database — a limitation the record describes as the basis that let Xyrem reach market.
4. Watch the § 102(e) trap: References like US 2004/0019794 (Moradi) and US 2003/0093295 (Lilly) published after the 2002‑12‑17 filing; they can only be prior art via pre‑AIA § 102(e) if their US filing dates precede the applicant's date. They cannot support § 102(a)/(b).

Confidence/limitations: Claim mapping above is my analytical assessment against the references' abstracts and the prosecution history, not a re‑reading of every reference's full disclosure. I did not independently confirm the bibliographic dates of every listed item; the dates for items 1–18 and 19–29 are drawn from the family's own "References Cited" list and are reliable, while a small number of published‑application dates (noted) should be spot‑checked against USPTO PAIR if precision matters. The PTAB record shows IPR2015‑00554 and IPR2015‑01818 (Final Written Decisions) and CBM2014‑00151 (not instituted) involving this family; I was not able to retrieve the specific art asserted in those proceedings within this session, so I have not attributed particular references to them.

I'll ground this analysis in the actual prior-art record for US 7,668,730. Let me pull the full citation list and the PTAB proceedings that challenged this family.

Now let me pull the exact grounds of the PTAB final written decision and the Federal Circuit affirmance, since these directly address § 103 obviousness of these very claims.

Let me confirm the second PTAB case listed on the patent (IPR2015-01818) and its ground, plus the ACA's mapping of key limitations.

Obviousness Analysis — U.S. Patent No. 7,668,730 B2

"Sensitive drug distribution system and method"
Reardan, Engle & Gagne · App. 10/322,348 filed 2002‑12‑17 · Granted 2010‑02‑23 · 11 claims · Original assignee JPI Commercial LLC; current assignee Jazz Pharmaceuticals, Inc.
Source: https://patents.google.com/patent/US7668730/en

Threshold note on scope. This is not a hypothetical analysis. Claims 1–11 of this exact patent were held unpatentable under § 103 by the PTAB on 2016‑07‑27 in Par Pharm., Inc. v. Jazz Pharms., Inc., IPR2015‑00554 (with IPR2015‑01818, Wockhardt Bio AG, joined), and that decision was affirmed in Jazz Pharms., Inc. v. Amneal Pharms., LLC, 895 F.3d 1347 (Fed. Cir. 2018). I therefore treat the PTAB/Federal Circuit record as the primary evidence of what the art discloses and what motivated combination, and I use the examiner‑cited references in the "Citations" section of the patent page as the basis for an independent, district‑court‑style § 103 analysis that does not depend on the "Advisory Committee Art" (ACA) at all.

1. Legal framework and representative claim

Under Graham v. John Deere Co., 383 U.S. 1, 17–18 (1966), the inquiry is: scope and content of the prior art; differences between the prior art and the claims; level of ordinary skill; and secondary considerations. Motivation to combine is a question of fact (Apple v. Samsung, 839 F.3d 1034, 1051 (Fed. Cir. 2016) (en banc)), and the Federal Circuit in Jazz v. Amneal expressly held that KSR does not impose "a rigid requirement to identify both a problem to be solved in the art and a finite universe of potential options."

Level of ordinary skill (as found by the Board, and unchallenged on appeal): a pharmacist or computer scientist "having familiarity with computerized drug distribution procedures." That is a low bar and is important: the "computerized" aspects of these claims (a relational database, queries, periodic reports) were, by 2001, entirely conventional.

Because the patent bears a 2002‑12‑17 filing/priority date, the pre‑AIA § 102(b) critical date is 2001‑12‑17. Only references publicly accessible before that date can be § 102(b) art.

Claims 1, 2, 7, 8, 9, 10 and 11 are independent; claims 3, 4, 5 and 6 depend from claim 2. All independent claims share the same eight-step skeleton (claim 10 adds "manufacturing GHB" and "providing manufactured GHB only to the exclusive central pharmacy"). Claim 1 is representative:

2. The prior art actually in the record

2a. References cited on the face of the patent ("Citations (42)")

The list at the patent page includes, inter alia: US 3,556,342; US 4,847,764; US 4,976,351; US 5,737,539; US 5,845,255 (Mayaud); US 5,924,074 (Evans); US 6,021,392 (Pyxis); US 6,045,501 (Elsayed); US 6,055,507 (Cunningham); US 6,112,182 (Akers); US 2001/0001144 A1 (Kapp); US 6,315,720 B1 (Williams/Celgene); US 2001/0042050 A1; US 2001/0047281 A1 (Keresman); US 2002/0032581 A1 (Reitberg); US 2002/0032582 A1; US 2002/0042725 A1 (Mayaud); US 2002/0042762 A1; US 2002/0052762 A1; US 2002/0161607 A1; US 2003/0046110 A1; US 2003/0050802 A1; US 2003/0110060 A1; US 2003/0127508 A1; US 2003/0144876 A1; US 2003/0229519 A1 (Eidex) — with the list continuing past the truncated US 2002/0010661 entry.
⚠️ Honest limitation: the Google Patents rendering truncates the "Citations (42)" list, so I can only characterize the subset I could verify. I do not assert what the unlisted/truncated members disclose. Also note several of these (e.g., the US 2003/… publications filed in 2002–2003) may not qualify as § 102(b) art against a 2001‑12‑17 critical date and would have to be evaluated under § 102(a)/(e).

Two members of the Williams/Celgene family beyond the one shown were cited during prosecution and are described in the file record: US 6,561,977 B2 and US 6,755,784 B2 ("Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated"). Prosecution statements confirm the Examiner and applicant treated these as material. (File‑record summary: https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1458364](/patent/1458364)/...)

2b. The ACA (the art that actually killed the patent)

• Ex. 1003 — FDA Peripheral & Central Nervous System Drugs Advisory Committee, Transcript and Slides (June 6, 2001)
• Ex. 1004 — R. B. Mani, FDA, Preliminary Clinical Safety Review of NDA 21‑196 (May 3, 2001)
• Ex. 1005 — Xyrem® (sodium oxybate) oral solution NDA #21‑196: Briefing Booklet (May 3, 2001)
• Ex. 1006 — Xyrem Prescription and Distribution Process Video and Transcript (Feb. 2, 2001)

Publicly accessible on the FDA website linked from the Federal Register notice, 66 Fed. Reg. 24,391 (May 14, 2001), no later than 2001‑10‑04 — more than two months before the critical date. Fed. Cir. slip op. at 6–8, 12–17: https://www.govinfo.gov/content/pkg/USCOURTS-ca13-17-01675/pdf/USCOURTS-ca13-17-01675-0.pdf

2c. The secondary references in the IPR

• Korfhage, Information Storage and Retrieval (John Wiley & Sons 1997) — distributed databases / single query over multiple physical databases.
• Talk About Sleep, "An Interview with Orphan Medical" (Feb. 12, 2001) (Ex. 1033) — "a central pharmacy that will handle the delivery of medicine to the patients"; physician faxes the prescription to that pharmacy, which "set[s] up a delivery time directly to the patient."
• Honigfeld et al., "Reducing Clozapine‑Related Morbidity and Mortality: 5 Years of Experience with the Clozaril National Registry," J. Clin. Psychiatry 59 (suppl. 3): 3–7 (1998) (Ex. 1034) — "The heart of the CNR is an integrated, computerized, confidential database that is maintained by the manufacturer"; all physicians and pharmacists "must agree to abide by the package labeling requirements and register with the CNR"; patients are screened through the CNR before treatment; full‑time staff review data retrospectively to identify discrepancies and institute corrective actions including education and de‑registration; 97% adherence.
• Elsayed et al., US 6,045,501 (issued 2000‑04‑04) (Ex. 1035) — one or more computer databases/computer‑readable storage media for registering prescribers, pharmacies and patients; registration information provided "to the manufacturer or distributor"; only registered pharmacies may dispense.
• Lilly et al., US 2004/0176985 A1 (Ex. 1036) — prescription‑tracking with drug/doctor/pharmacist/patient data stored for a plurality of patients and pharmacies.
  ⚠️ Caveat on Lilly: US 2004/0176985 A1 published 2004‑09‑09 and its earliest asserted priority is 2002‑01‑31 — after the 2001‑12‑17 critical date. It is therefore questionable § 102 prior art against the '730 patent. I would not build a standalone rejection on it.

Valuck Declaration (element‑by‑element mapping): https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1459990](/patent/1459990)/...
Final Written Decision: https://ipwatchdog.com/wp-content/uploads/2018/01/730-final-written-decision.pdf
Institution Decision: https://paragraphfour.com/uploads/cases15/ipr15-0551IRD.pdf

3. Ground A — ACA alone (and ACA + Korfhage): the ground that prevailed

This is the cleanest § 103 case, because the ACA is the drug sponsor's own proposed Xyrem distribution system placed in the public record before the critical date.

Motivation to combine / why non‑obviousness arguments failed:

• The Board held the ACA "suggest[s], if not teach[es] expressly, the step of confirming with a patient that educational materials were received and/or read prior to shipping Xyrem."
• No teaching away. Jazz argued the Committee preferred post‑shipment education. The Board and Federal Circuit rejected this under DePuy Spine and In re Fulton: "a reference does not teach away … if it merely expresses a general preference for an alternative … but does not criticize, discredit, or otherwise discourage investigation." Asking the question, the Board held, "suggested at least some value" in the claimed order of steps.
• Claims 2 and 10 of the sibling '988 patent (and claims reciting a database "distributed over multiple computers") fell as obvious over ACA + Korfhage for "cost, efficiency, and the anticipated volume of prescription‑related information." The Federal Circuit affirmed, holding a distributed database was "a predictable use of a known distributed data system according to its established function" — and that Jazz's reading of KSR would reinstate "the exact sort of 'rigid preventative rule' the Court rejected."

Result: claims 1–11 of the '730 patent unpatentable over the ACA (2016‑07‑27), affirmed 2018‑07‑13.

4. Ground B — Talk About Sleep + Honigfeld + Elsayed (motivation: centralize the compliance check)

This ground has the virtue of using only unquestionably pre‑critical‑date art (Feb. 2001, 1998, and 2000 respectively).

• TAS supplies the exclusive central pharmacy + direct‑to‑patient mailing architecture (the preamble, steps 1.1 and 1.6) — but on its own lacks the "exclusive computer database … processed only by the exclusive central pharmacy" limitation (step 1.2) and step 1.5.
• Honigfeld supplies those missing pieces: a manufacturer‑maintained integrated computerized database, mandatory registration of prescribers and pharmacists, pre‑treatment screening against the database, retrospective review by dedicated staff to detect discrepancies and compliance failures, and de‑registration as a sanction. That is steps 1.2, 1.3, 1.5 and 1.8, and it supports dependent claim 4/5 (blocking shipment on an abuse pattern).
• Elsayed (US 6,045,501) supplies the registered‑prescriber/pharmacy/patient database and the requirement that registrations go to the manufacturer or distributor.
• Stated motivation (Valuck ¶ 124): "[I]t would have required no more than routine skill to modify Talk About Sleep's method to centralize the checking for compliance … at the central pharmacy as taught in Honigfeld, Elsayed, and Lilly, and mail[] the prescription drug to the patient only if no records of non‑compliance were found."

Weakness to be candid about: both the Board (in the related '106 and '059 proceedings) and Jazz correctly observed that Honigfeld and Elsayed teach decentralized dispensing through multiple registered pharmacies, and that the prescriber sends the prescription to the pharmacy, not to a central database, and that TAS "does not disclose entering prescription information into 'an exclusive computer database…' as recited in step 1.2." That is precisely the point of novelty Jazz relied on. It is a genuine factual gap that a district court could find persuasive if the ACA were excluded. It is also why Ground A (ACA), not Ground B, is the ground that actually invalidated the claims, and why I flag it as the closer question. Ground B becomes much stronger when TAS is supplemented by Pyxis (US 6,021,392) and Cunningham (US 6,055,507) for centralized drug‑distribution management and shipment tracking, or when the exclusivity requirement is met by the ACA.

5. Ground C — Independent combination built solely on the examiner‑cited references

This ground does not rely on the ACA and is the one I would press in a district‑court invalidity contention.

Primary reference: Williams et al., US 6,315,720 B1 ("Methods for delivering a drug to a patient while restricting access … contraindicated"), with its siblings US 6,561,977 B2 and US 6,755,784 B2, and Celgene sibling Elsayed, US 6,045,501.
These teach, as recited in the '730 specification's own discussion of them: a computer readable storage medium in which the prescriber, pharmacy and patient are registered; use of that medium to educate and reinforce the actions of patients, prescribers and pharmacies; and assigning patients to risk groups based on collected information in order to limit unauthorized and inappropriate distribution of the drug. That maps to steps 1.2 (registry database), 1.3 (prescriber registration/eligibility), 1.4 (education), 1.6 (limiting/blocking distribution) and the dependent "risk group"/blocking concepts.

Secondary references supplying the remaining limitations:

Motivation to combine (Ground C): All of these references are in the same field of endeavour and address the same problem — the '730 specification's own statement of the problem ("Dr. shopping, diversion, and pharmacy thefts"; patients "obtain[ing] prescriptions from multiple doctors, and hav[ing] them filled at different pharmacies"; a drug that "must be prescribed by a licensed physician"). Under KSR, where the references are analogous, address a known problem, and the combination is "a predictable use of prior‑art elements according to their established functions," an express teaching, suggestion or motivation is unnecessary. Concretely:

1. Celgene's restricted‑access registry (US 6,315,720 / 6,561,977 / 6,755,784 / 6,045,501) already solves "how do I keep a dangerous but beneficial drug out of contraindicated hands" via registration + education + risk grouping + blocking.
2. Mayaud and Eidex already solve "how do I detect a patient or prescriber who is shopping" via a shared prescription database with abuse/fraud screening. Combining them is the natural step of feeding the registry database into the abuse‑screening engine.
3. TAS/ACA supplies the last architectural choice — one central pharmacy that mails direct to the patient — which is itself disclosed for this very drug and which the Federal Circuit has already characterized as a predictable, established distribution model.
4. Claim 8's "GHB" limitation adds only the identity of the drug, which is not a patentable difference where the entire framework is drug‑agnostic and GHB/Xyrem is expressly named in the prior art (TAS, ACA).

Dependent claims 3–6 add nothing unobvious: claim 3 (central pharmacy controls the database) is the necessary consequence of the registry being "maintained by the manufacturer" (Honigfeld); claims 4–5 (selectively blocking shipment on patient‑associated abuse pattern) is disclosed by Honigfeld's de‑registration/discrepancy actions and by the Celgene risk‑group restrictions; claim 6 (GHB) is the named drug of TAS/ACA.

6. Secondary considerations — considered and outweighed

Jazz's likely Graham factors, and the record response (Petitioner's arguments in the '730 IPR: https://ptacts.uspto.gov/ptacts/public-informations/petitions/1459990/...):

• Commercial success (Xyrem). No nexus: any success is attributable to the pharmaceutical effect of GHB and to the physical characteristics of the approved product, not the claimed distribution steps; and Jazz cannot show "any unique property of the claimed distribution program actually drove sales." Importantly, listing the '730 in the Orange Book as a REMS‑linked patent does not itself establish nexus.
• Long‑felt but unmet need / failure of others. Substantially undercut by the art itself: clozapine (Honigfeld/Clozaril National Registry, 1998), thalidomide (Celgene/Williams) and Xyrem's own proposed program (ACA, Feb.–June 2001) all predate the '730 filing. As Petitioner put it, "efficacious distribution programs for hazardous, but therapeutically beneficial prescription drugs were known in the art," and "[a]pplication of known distribution programs … required no more than routine skill."
• Copying. Not probative in the ANDA/generic context.
• Unexpected results. None demonstrated; the claimed program provides no "significant and practical advantage over the closest prior art — the ACA — which discloses all of the limitations of the claimed distribution program."

I am not aware of any countervailing secondary‑consideration evidence (praise, licensing, initial skepticism) in the record strong enough to overcome the ACA alone, and the Federal Circuit did not disturb the Board's obviousness conclusion.

7. Claim‑construction issues that materially affected the § 103 analysis

Two constructions decided in Jazz's favor on appeal and worth flagging because they broaden the claims and thus widen the prior‑art coverage:

• "periodic reports" = reports generated "at regular intervals or intermittently" (Jazz argued "only at regular, fixed intervals"; rejected).
• "information identifying" patients/prescribers = not limited to the specific items listed in the specification and not requiring all listed types.

Both constructions were affirmed as supported by the intrinsic record.

8. Bottom line

Answer: Claims 1, 2, 7, 8, 9, 10 and 11 (and, through claim 2, dependent claims 3, 4, 5 and 6) of US 7,668,730 are obvious under 35 U.S.C. § 103, both over the Advisory Committee Art alone/with Korfhage, and over combinations of the examiner‑cited art (principally the Celgene/Williams restricted‑access registry references in view of Mayaud and Eidex, with Talk About Sleep supplying the single‑central‑pharmacy, mail‑direct‑to‑patient architecture). The motivation in every combination is the same and is stated on the face of the patent itself: prevent "Dr. shopping, diversion, and pharmacy thefts" for a sensitive drug that "must be prescribed by a licensed physician," by centralizing prescriber credentialing, patient education and abuse screening in one database. This is not merely my conclusion — it is the holding of the PTAB, affirmed by the Federal Circuit, and the patent page now records the patent as "Expired – Fee Related," adjusted expiration 2024‑06‑16, with the family still in litigation (D.N.J. cases 2:10‑cv‑06108, 2:12‑cv‑06761, 2:13‑cv‑07884, 2:14‑cv‑04467, 2:14‑cv‑07757, 2:15‑cv‑05619, 2:15‑cv‑06548, 2:17‑cv‑05487, 2:18‑cv‑00029; E.D.N.Y. 2:17‑cv‑04439) and PTAB case CBM2014‑00151 not instituted.

Explicit confidence and uncertainty disclosures

• High confidence in the ACA ground, its reference identities, its 2001‑10‑04 public‑accessibility finding, the claim constructions, and the affirmance: all are directly documented in the Federal Circuit opinion and the PTAB final written decision linked above.
• High confidence in the content of Honigfeld, Elsayed, Korfhage and Talk About Sleep as quoted in the IPR record.
• Medium confidence in the exact page/line cites within the ACA exhibits (e.g., "Ex. 1004 at 115 §14.4," "Ex. 1003, 177:24–178:11"); these are reproduced from the decision and party filings, not from my independent inspection of the exhibits.
• Low confidence / flagged: (i) the subject matter of the truncated members of the "Citations (42)" list beyond US 2002/0010661 — I did not characterize them and do not assert what they disclose; (ii) the § 102 status of US 2004/0176985 A1 (Lilly), which appears to post‑date the 2001‑12‑17 critical date; (iii) the "INVALID / VALID" annotation for 7,668,730 in the third‑party table at usinventor.org, which I could not verify against a docket and which conflicts in part with the Federal Circuit affirmance; treat it as unverified.
• I did not independently verify the current litigation status of the listed D.N.J./E.D.N.Y. cases or the settled post‑2018 outcomes described in Jazz's investor filings; those are recited from the sources found, not from independent docket review.